63rd American Society of Hematology (ASH) Annual Meeting
December 2021
- Comprehensive in Vitro Characterization of CXCR4-WHIM variants to Decipher Genotype–Phenotype Correlations in WHIM Syndrome
- Oral Administration of Mavorixafor, a CXCR4 Antagonist, Increases Peripheral White Blood Cell Counts across Different Disease States
- Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström’s Macroglobulinemia with MYD88 and CXCR4 Mutations
- Mavorixafor, an Oral CXCR4 Antagonist, for Treatment of Patients With WHIM Syndrome: Results From the Long-Term Extension of theOpen-Label Phase 2 Study